RELMADA THERAPEUTICS, INC. — Form 4
Filed September 11, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 58/100
What the filing says
Chief Executive Officer TRAVERSA SERGIO (RLMD) bought 200K shares (~$828K) on the open market (12% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.